iv για αντιμετώπιση μετεγχειριτικού άλγους.
IV diclofenac was evaluated for the short-term management of moderate to
severe postoperative pain in two double-blind, placebo and active controlled,
multiple-dose clinical trials.
o Injectable diclofenac was consistently better in improving standard
measures of acute pain (Summed pain intensity difference [SPID], pain
intensity difference [PID], etc.) and reduced the dose, time to
administration, and overall need for rescue opioid therapy when
compared to placebo.
o There were no consistent differences between IV diclofenac and IV
ketorolac as assessed by a number of pain measures including SPID,
PID, percentage of patients with reduced pain intensity >30% from
baseline, patient global assessment or consumption of rescue opioids. In
the study of patients having orthopedic surgery, there was a statistical
difference in favor of diclofenac over ketorolac in total morphine
consumed over 5 days (11.8 mg vs. 18.1 mg, respectively). However,
the clinical significance of a difference of 6 mg of morphine consumed
over 5 days is not clear. Additionally, time for PID to become
significant vs. placebo was 10 minutes for diclofenac and 30 minutes for
ketorolac.
o Differences in length of stay were not reported.
o There are no studies comparing IV diclofenac to IV acetaminophen or
IV ibuprofen.
There was a single study in patients having third molar extraction comparing IV
diclofenac to IV ketorolac and placebo. No differences were noted between
active treatment groups and both groups were statistically better in improving
pain measures vs. placebo.
Δεν είναι ορατοί οι σύνδεσμοι (links).
Εγγραφή ή
Είσοδος